• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

home / authors / safety-of-ozanimod-in-multiple-sclerosis-dose-blinded-extension-of-a-randomized-phase-ii-study-published-online-july-25-2018-mult-scler-2018-1352458518789884-doi-101177-1352458518789884

Articles

© 2024 MJH Life Sciences
AJMC®
All rights reserved.